Genmab — November 2016
-
-
CITAT START-→ Biotechnology giant Amgen Inc. (AMGN) is studying a takeover offer for smaller rival Actelion Ltd. (ATLN.VX) and might approach the Swiss drug maker as soon as this week, Bloomberg News reported Tuesday, citing two people with knowledge of the matter. ← CITAT SLUT
-
Artiklen omhandler et forestående Amgen takeover af Actelion og den nye artikel fra i går aftes vedrørende et JnJ takeover er nærmest et copy paste. En markant forskel er dog at Bloomberg i Amgen artiklen reelt har fået en kommentar fra Actelion.
-
Herudover vil jeg bringe følgende meget tankevækkende artikel i erindring:
-
CITAT START→ Forget whatever rumors you’ve heard about Actelion fending off takeover approaches from its larger rivals, CEO Jean-Paul Clozel says.
As the skipper told Bloomberg, Actelion hasn’t yet had to do any such thing--and it hopes it doesn’t going forward.
“We at Actelion--the board of directors, the management, the employees--are all building a company and not thinking about being sold the next day,” Clozel said. “If we want to continue to create shareholder value, the best for us is to -
remain independent.” ← CITAT SLUT
-
Artiklen fra Fierce Pharma lyder 100% som noget Winkel kunne have udtalt tilbage I April måned. Hvad vil jeg sige med disse to links og I særdeleshed det første link. Well, jeg ved det ikke, men nok blot at man ikke nødvendigvis skal sælge skinder før bjørnen er skudt !!!!
-
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind